Debt-to-equity in % of Janux Therapeutics, Inc. from Q1 2022 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Janux Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q3 2025.
  • Janux Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 4.17 %, a 32% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

Janux Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 4.17 -1.96 -32% Sep 30, 2025
Q2 2025 4.28 -2.74 -39% Jun 30, 2025
Q1 2025 4.47 -4.58 -50.6% Mar 31, 2025
Q4 2024 4.83 -7.26 -60% Dec 31, 2024
Q3 2024 6.13 -6.74 -52.3% Sep 30, 2024
Q2 2024 7.02 -6.54 -48.2% Jun 30, 2024
Q1 2024 9.05 -4.01 -30.7% Mar 31, 2024
Q4 2023 12.1 +1.62 +15.5% Dec 31, 2023
Q3 2023 12.9 +4.88 +61% Sep 30, 2023
Q2 2023 13.6 +7.88 +139% Jun 30, 2023
Q1 2023 13.1 +9.53 +270% Mar 31, 2023
Q4 2022 10.5 Dec 31, 2022
Q3 2022 8 Sep 30, 2022
Q2 2022 5.68 Jun 30, 2022
Q1 2022 3.53 Mar 31, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.